InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to -$0.44.
- InMed Pharmaceuticals' EPS (Weighted Average and Diluted) rose 8376.38% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.45, marking a year-over-year increase of 5278.18%. This contributed to the annual value of -$8.36 for FY2025, which is 5847.58% up from last year.
- Per InMed Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.44 for Q3 2025, which was up 8376.38% from -$1.83 recorded in Q2 2025.
- In the past 5 years, InMed Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of -$0.14 in Q2 2023 and a low of -$15.24 during Q3 2023
- Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$3.58 (2024), whereas its average is -$3.91.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 256238.74% in 2024, then skyrocketed by 8376.38% in 2025.
- Quarter analysis of 4 years shows InMed Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$6.14 in 2022, then surged by 39.58% to -$3.71 in 2023, then increased by 1.89% to -$3.64 in 2024, then soared by 87.91% to -$0.44 in 2025.
- Its last three reported values are -$0.44 in Q3 2025, -$1.83 for Q2 2025, and -$1.94 during Q1 2025.